Fig. 1From: Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world studyFlowchart showing patient selection. PLD, pegylated liposomal doxorubicin; pCR, pathological complete response; PSM, propensity score matchingBack to article page